| Autor: |
Reut Kassif Lerner, Michal Stein Yeshurun, Rina Hemi, Nahid Zada, Keren Asraf, Ram Doolman, Stefanie W. Benoit, Maria Helena Santos de Oliveira, Giuseppe Lippi, Brandon Michael Henry, Itai M. Pessach, Naomi Pode Shakked |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of Personalized Medicine; Volume 12; Issue 4; Pages: 622 |
| ISSN: |
2075-4426 |
| Popis: |
One of the major challenges for healthcare systems during the Coronavirus-2019 (COVID-19) pandemic was the inability to successfully predict which patients would require mechanical ventilation (MV). Angiotensin-Converting Enzyme 2 (ACE2) and TransMembrane Protease Serine S1 member 2 (TMPRSS2) are enzymes that play crucial roles in SARS-CoV-2 entry into human host cells. However, their predictive value as biomarkers for risk stratification for respiratory deterioration requiring MV has not yet been evaluated. We aimed to evaluate whether serum ACE2 and TMPRSS2 levels are associated with adverse outcomes in COVID-19, and specifically the need for MV. COVID-19 patients admitted to an Israeli tertiary medical center between March--November 2020, were included. Serum samples were obtained shortly after admission (day 0) and again following one week of admission (day 7). ACE2 and TMPRSS2 concentrations were measured with ELISA. Of 72 patients included, 30 (41.6%) ultimately required MV. Serum ACE2 concentrations >7.8 ng/mL at admission were significantly associated with the need for MV (p = 0.036), inotropic support, and renal replacement therapy. In multivariate logistic regression analysis, elevated ACE2 at admission was associated with the need for MV (OR = 7.49; p = 0.014). To conclude, elevated serum ACE2 concentration early in COVID-19 illness correlates with respiratory failure necessitating mechanical ventilation. We suggest that measuring serum ACE2 at admission may be useful for predicting the risk of severe disease. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
